Antihypertensive Drugs Market Size To Expand at a Notable CAGR Of 2.67% During 2018 - 2023

Pune, India, January 2019/MRFR Press Release/- Market Research Future has published a half-cooked research report on the Global Antihypertensive Drugs Market

Overview

The global antihypertensive drugs market is expected to surge at 2.67% CAGR during the forecast period (2018-2023) to reach a valuation of USD 41,123.1 million by 2023, asserts Market Research Future (MRFR) in its latest report. It previously stood at USD 34,843.6 million in 2017.

Increasing prevalence of hypertension is the primary driver of the antihypertensive drugs market. According to the World Health Organization (WHO), adults above the age of 18 with hypertension in 2017 had risen sharply from the previous share of 22.1% in 2015. Rising initiatives by government and non-government organizations for creating awareness of the medical condition can boost the market volume considerably. In addition, updated research on drugs in clinical trials can open up new growth avenues for the antihypertensive drugs market till 2023.

Increase in cases of chronic diseases such as heart conditions, kidney problems, and others is projected to provide the antihypertensive drugs market a much-needed impetus. Coronary and renal failure rates are growing sharply inducing the demand for these drugs. According to the Center for Disease Control & Prevention in 2017, nearly 735,000 Americans have had heart attacks which can cause hypertension. Moreover, the entry of generic drugs which can lower the treatment costs of patients tremendously is projected to bolster market demand.

But side-effects of these drugs and preference of non-pharmacological therapies such as acupuncture can hamper the market growth.

Segmentation

The antihypertensive drugs market is segmented by therapeutic class, type, and distribution channel. 

By therapeutic class, diuretics have captured 28% market share in 2017, followed by ACE inhibitors (17%) and ARBs (15%). Diuretics can showcase 2.85% CAGR over the forecast period to generate USD 11,865.9 million by 2023. The use of diuretics to lower the salt and water content to reduce the probability of stroke and heart failure can bode well for the segment growth. On the other hand, the ACE inhibitors segment is likely to exhibit 3.10% CAGR over the forecast period to accrue close to USD 7,227.8 million by 2023. This can be credited to the rising indication of ACE inhibitors by doctors in New Zealand for treating hypertension.

By type, primary hypertension took the lead with 86% share of the antihypertensive drugs market in 2017, followed by secondary hypertension (14%). Primary hypertension can exhibit 2.53% CAGR over the forecast period to touch a size of USD 35,292.3 million by 2023. On the flip side, secondary hypertension is expected to exhibit 3.60% CAGR over the forecast period to generate close to USD 5,830.9 million by 2023. This can be attributed to rise in cardiovascular and kidney disorders.

By distribution channel, retail pharmacy had 45% share in 2017, followed by hospital pharmacy (34%), e-commerce websites & online drug stores (14%), and others (7%). Retail pharmacy can exhibit 2.67% CAGR during the forecast period to accrue close to USD 18,695.2 million by 2023. Although retail pharmacy had a bigger share in the market, it can lose its position to e-commerce websites & online drug stores. The latter can generate close to USD 6,324.9 million by 2023 at a CAGR of 4.24% over the forecast period.

Regional Analysis

Geographical analysis of the global antihypertensive drugs market includes Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

Americas accounted for 36.6% share in 2017, followed by Europe (28.2%) and APAC (22.8%) respectively in the same year. The Americas can dominate the antihypertensive drugs market thanks to North America. Early discernment of hypertension in patients, advanced diagnosis infrastructure, and demand for accurate diagnosis and treatment of the condition are factors driving the regional growth. The Americas are predicted to generate nearly USD 8,059.2 million by 2023.

The Europe region is plagued by increasing incidence of cardiovascular diseases due to rise in cases of systolic and diastolic blood pressure. Combination of antihypertensive drugs as a single pill is proving to be a popular pharmacological therapy is expected to bode well for the market. The region is touted to contribute USD 11,269.5 million to the antihypertensive drugs market by 2023.

The APAC region is projected to generate USD 9,862.4 million by 2023. This can be attributed to the growing antihypertensive drugs market in India, Japan, and China. Lifestyle changes and high stress levels of citizens are prime factors driving the regional market.

Competitive Analysis:

Eminent names mentioned in the antihypertensive drugs market report include Pfizer, Inc. (U.S.), Sanofi S.A. (France), Novartis AG (Switzerland), United Therapeutics Corporation (U.S.), Johnson & Johnson Services, Inc. (U.S.), Merck KGaA (Germany), AstraZeneca (U.K.), Bayer AG (Germany), Daiichi Sankyo Company, Ltd. (Japan), Takeda Pharmaceutical Company (Japan), and Boehringer Engelheim GmbH (Germany). Investments in research and development and increasing the outcome of clinical trials for tackling the challenge of patent expiry of drugs is the main strategy of the players. In 2017, Daiichi Sankyo announced the success of Esaxerenone in its phase II clinical trial and moved it to phase III for further development and study.

Browse Complete Report @  https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347